Figure 7.

Tivantinib mediates therapeutic effects in EAE

(A–E) Intraperitoneal injection of vehicle or Tivantinib (10 mg/kg) in C57BL/6J mice beginning at the disease onset of EAE every 2 days. (A) Schematic diagram of Tivantinib administration in EAE. (B) Clinical scores after EAE induction. (C) The cumulative and maximum clinical score of EAE. (D) Sections of paraffin-embedded spinal cord tissues were stained with H&E and LFB. (E) FACS analysis of live CD4⁺, CD8⁺, CD11b⁺, and CD11b⁻ cells gate on CD45^hi cells in the CNS on the day 30 after EAE induction.

(F) The numbers of CD4⁺, CD8⁺, CD11b⁺, and CD11b⁻ cells gate on CD45^hi cells in the CNS on the 30 days after the induction of EAE. Data represent means ± SEM from six biological duplicates. Statistical analysis was performed using one-way ANOVA(B, F) or unpaired Student’s t test (C). ∗p < 0.05, ∗∗p < 0.01.